Alnylam Pharmaceuticals | ALNY - Umsatzkosten





Umsatzkosten Veränderung Datum
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Amgen USD 1.87B 271M 2026-06
BioCryst Pharmaceuticals USD 3.84M 5.68M 2026-06
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Incyte USD 104.96M 457K 2026-06
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
Moderna USD 93M 862M 2026-06
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Novartis USD 3.46B 83M 2026-03
PTC Therapeutics USD 39.61M 23.31M 2026-03
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Sangamo BioSciences 2.42M 1.11M 2024-06
Sanofi EUR 3.14B 618M 2026-03
Sarepta Therapeutics USD 150.1M 40.64M 2026-06
Takeda JPY 517.6B 42.94B 2026-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Vertex Pharmaceuticals USD 489.2M 96.4M 2026-06
Xencor USD 61.66M 50.95M 2025-06